Table 2.
Clinicopathological and molecular factors associated with LNM in PTC in the FUSCC cohort
| Variables | Univariate analysis
|
Multivariate analysis
|
||||
|---|---|---|---|---|---|---|
| P-value | OR | 95% CI for OR | P-value | OR | 95% CI for OR | |
| Female | 0.094 | 0.422 | 0.154–1.159 | |||
| Age ≥45 years | 0.001# | 0.219 | 0.091–0.524 | 0.001# | 0.195 | 0.076–0.501 |
| Tumor size (cm) | ||||||
| 2–4 | 0.045# | 3.113 | 1.035–22.375 | 0.062 | 4.740 | 0.927–24.290 |
| >4 | 0.841 | 1.283 | 0.112–14.702 | |||
| Multifocality | 0.431 | 1.484 | 0.556–3.960 | |||
| HT | 0.113 | 0.450 | 0.168–1.208 | |||
| ETE | 0.120 | 5.311 | 0.646–43.664 | |||
| BRAFV600E | 0.394 | 1.424 | 0.632–3.208 | |||
| DUSP4 (greater than cutoff)* | 0.003# | 4.064 | 1.632–10.124 | 0.004# | 4.215 | 1.565–11.347 |
Notes:
#
Statistically significant;
*
DUSP4 expression level greater than the best cutoff value for the prediction of LNM.
Abbreviations: LNM, lymph node metastasis; PTC, papillary thyroid cancer; FUSCC, Fudan University Shanghai Cancer Center; OR, odds ratio; CI, confidence interval; HT, Hashimoto’s thyroiditis; ETE, extrathyroidal extension; DUSP4, dual specificity phosphatase 4.